Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday

Key Points

• Atea Pharmaceuticals is set to release its Q2 2025 earnings on August 6th, with analysts expecting a loss of ($0.44) per share for the quarter.
• The stock is currently trading at $3.80, having a market cap of $325.20 million and highlighting a 52-week range of $2.45 to $4.14.
• Jane Street Group LLC recently increased its stake in Atea Pharmaceuticals by 80.4%, owning 0.12% of the company after acquiring additional shares.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.16. On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Stock Performance

NASDAQ AVIR traded down $0.17 on Friday, reaching $3.47. The stock had a trading volume of 313,746 shares, compared to its average volume of 376,402. The stock has a market cap of $296.96 million, a P/E ratio of -2.10 and a beta of 0.25. The business's 50-day moving average price is $3.41 and its 200 day moving average price is $3.13. Atea Pharmaceuticals has a 12-month low of $2.45 and a 12-month high of $4.14.

Analyst Upgrades and Downgrades

A number of research firms have commented on AVIR. Wall Street Zen upgraded shares of Atea Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Morgan Stanley decreased their target price on shares of Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th.

Institutional Trading of Atea Pharmaceuticals

A hedge fund recently raised its stake in Atea Pharmaceuticals stock. Jane Street Group LLC raised its stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 80.4% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 102,607 shares of the company's stock after buying an additional 45,716 shares during the quarter. Jane Street Group LLC owned about 0.12% of Atea Pharmaceuticals worth $307,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 86.67% of the company's stock.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.